Navigation Links
AstraZeneca Announces Top-Line Results of OSKIRA-4 Phase IIb Study of Fostamatinib as a Monotherapy for Rheumatoid Arthritis
Date:12/13/2012

SOUTH SAN FRANCISCO, Calif., Dec. 13, 2012 /PRNewswire/ -- AstraZeneca today announced top-line results of OSKIRA-4, a Phase IIb monotherapy study of fostamatinib, the first kinase inhibitor with selectivity for SYK (spleen tyrosine kinase) in development as an oral treatment for rheumatoid arthritis (RA).

OSKIRA-4 was a six month study evaluating improvements in signs and symptoms of RA in 280 patients who had never previously used a disease-modifying anti-rheumatic drug (DMARD), were DMARD intolerant or had an inadequate response to DMARDs and were randomised to receive fostamatinib as a monotherapy, adalimumab as a monotherapy, or placebo.  Three dose regimens of fostamatinib were evaluated in OSKIRA-4: 100mg twice daily, 100mg twice daily for a month followed by 150mg once daily, and 100mg twice daily for a month followed by 100mg once daily.

OSKIRA-4 had two primary objectives – a superiority comparison to placebo at 6 weeks and a non-inferiority analysis against adalimumab monotherapy at 24 weeks as measured by change from baseline in DAS28 score (a composite endpoint assessing signs and symptoms of RA).

In the OSKIRA-4 study, fostamatinib as a monotherapy met the first primary objective, showing a statistically significant superior DAS28 score change from baseline compared to placebo at 6 weeks at the 100mg twice daily dose and the 100mg twice daily for a month followed by 150mg once daily dose, but not at the 100mg twice daily for a month followed by 100mg once daily dose.

The OSKIRA-4 study did not meet its second primary objective as all fostamatinib monotherapy doses were inferior to adalimumab monotherapy at week 24 based on DAS28. The adalimumab monotherapy ACR20 result at the 24 week endpoint was 59%.

The safety and tolerability findings for fostamatinib as reported in the OSKIRA-4 study were generally consistent with that previously observed in the TASKi Phase II programme.  

Ma
'/>"/>

SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Zacks Bull and Bear of the Day Highlights: Discover Financial Services, POSCO, AstraZeneca, Bayer and Takeda Pharmaceutical
2. AstraZeneca And Cellworks Collaborate To Find New Treatment For Tuberculosis
3. Genpact and AstraZeneca Win Outsourcing Center and SSON Awards
4. AstraZeneca Acquires Neuroscience Assets From Link Medicine
5. AstraZeneca and Leading Academic Scientists to Collaborate on Alzheimers Disease Research
6. Founded by Enlight Biosciences, KNODE partners with AstraZeneca and Other Partners
7. Regulus Therapeutics Forms Strategic Alliance for Discovery, Development and Commercialization of microRNA Therapeutics with AstraZeneca
8. AstraZeneca And The Broad Institute Partner To Advance Discovery Of Antibacterial And Antiviral Agents
9. Isis Pharmaceuticals And AstraZeneca Form Strategic Alliance On RNA Therapeutics For Cancer
10. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
11. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... , Nov. 26, 2014 The medical ... a rate of 4%, with world market revenues ... Information. MRI and other types of medical imaging ... treatment of numerous medical conditions in children and ... techniques. Kalorama,s report, Medical Imaging Markets , ...
(Date:11/26/2014)... 25, 2014  At the American Dental Association,s Annual ... October, KaVo Kerr Group was honored to be part ... the opportunity to see and test the Best of ... deliver lectures on the latest developments in dental technology. ... new DEXIS CariVu Caries Detection Device and Kerr Demi ...
(Date:11/26/2014)...  Medtronic,s roughly $43 billion acquisition and ... in the media for its US Federal tax ... player in one of the fastest growing device ... research firm said  the two companies compete in ... of solutions spanning inpatient to home care, and ...
Breaking Medicine Technology:Kalorama: Steady Growth in the Medical MRI Market 2Kalorama: Steady Growth in the Medical MRI Market 3KaVo Kerr Group Showcased in Pride Institute Technology Expo at ADA Annual Meeting 2KaVo Kerr Group Showcased in Pride Institute Technology Expo at ADA Annual Meeting 3Medtronic - Covidien: Beyond Taxes, Deal Will Create Patient Monitoring Power, according to Kalorama Information 2Medtronic - Covidien: Beyond Taxes, Deal Will Create Patient Monitoring Power, according to Kalorama Information 3
... 2011 PDL BioPharma, Inc. (PDL, the Company) (NASDAQ: ... to exchange up to $180,000,000 in aggregate principal amount of ... a like principal amount of new 2.875% Series 2011 Convertible ... Holders that exchange their Old Notes will receive a like ...
... IRIDEX Corporation (Nasdaq: IRIX ) announced ... with Alcon, the global leader in eye care, headquartered ... GreenTip™ Soft Tip Cannula family of products and license ... IRIDEX GreenTip Soft Tip Cannula products are used in ...
Cached Medicine Technology:PDL BioPharma Inc. Announces Exchange Offer for Its 2.875% Convertible Senior Notes Due February 15, 2015 2PDL BioPharma Inc. Announces Exchange Offer for Its 2.875% Convertible Senior Notes Due February 15, 2015 3PDL BioPharma Inc. Announces Exchange Offer for Its 2.875% Convertible Senior Notes Due February 15, 2015 4IRIDEX Signs License and Distribution Agreement with Leader in Eye Care 2
(Date:11/26/2014)... Vultures have developed highly specialized ways of dealing with ... researchers report. The new research investigated the different ... the guts of 50 turkey vultures and black vultures ... the vultures had more than 500 different types of ... found. The findings suggest that a vulture,s digestive ...
(Date:11/26/2014)... number of emergency department visits in the United States rose ... million in 2011, according to the U.S. Centers for Disease ... people were going to ERs with non-urgent medical needs: 96 ... two hours of arriving at the ER. In 2010, that ... percent of patients arrived at the ER after normal business ...
(Date:11/26/2014)... HealthDay Reporter TUESDAY, Nov. 25, ... U.S. Food and Drug Administration will have many restaurant chains ... apply to movie theater popcorn and ice cream parlor fare. ... from home, often consuming less nutritious food and underestimating the ... a Monday afternoon news conference. Although listing calorie ...
(Date:11/26/2014)... need to take an active role in protecting their ... must make sure sports-playing teens have the right protective ... the American Migraine Foundation and a professor of medicine ... Ariz. in an American Migraine Foundation, said in a ... teens sports needs to have appropriate training. Teen sports ...
(Date:11/24/2014)... November 24, 2014 From embedded sensors and ... of fitness technology will take center stage at the ... at the 2015 International CES® , January 6, ... Level 2, Bellini 2004). The bond between fitness and technology ... less about devices and more about the human body. , ...
Breaking Medicine News(10 mins):Health News:ER Visits on the Rise, Study Reports 2Health News:Calorie Counts Mandated at Chain Restaurants, FDA Says 2Health News:Calorie Counts Mandated at Chain Restaurants, FDA Says 3Health News:Parents Need to Take Lead on Teen Concussion Prevention 2Health News:Next Wave Fitness Products Debut at FitnessTech Summit Living in Digital Times at the 2015 International CES 2Health News:Next Wave Fitness Products Debut at FitnessTech Summit Living in Digital Times at the 2015 International CES 3Health News:Next Wave Fitness Products Debut at FitnessTech Summit Living in Digital Times at the 2015 International CES 4
... American Botanical Council (ABC) has officially launched its Adopt-an-Herb ... tea ( Camellia sinensis ). For the next three ... to ensure that abstracts (summaries) of the latest published ... within ABC,s HerbMedPro database, one of the most robust ...
... American Life League will feature two of the most ... and Activism Week and Personhood Conference Jan. 21-23. , ... , , The TAW will ... launched the Born Alive Truth campaign during the 2008 presidential ...
... third of patients with suspect scans develop the disease within ... -- Among people whose brain scans show signs of multiple ... within about five years, researchers say. , The study ... variety of reasons, including migraines or head trauma. The scans ...
... , Company Appoints Tami Booth Corwin To New Position ... NEW YORK, Dec. 10 In its first major offline ... publisher of self-improvement books and products, to publish THE SPARK: ... Your Life. The book will give readers a proven ...
... racing to develop drugs that use the gene silencing mechanism ... Now, a new study opens up an entirely new possibility ... have demonstrated for the first time that RNA interference can ... , "Our data suggest that, at least in an ...
... Pharmaceuticals, Inc. ("Napo"),is pleased to announce a collaboration ... crofelemer for all indications in North America,Europe (excluding ... Crofelemer is Napo,s novel anti-secretory,gastrointestinal agent currently ... treatment of,chronic diarrhea in people living with HIV/AIDS ...
Cached Medicine News:Health News:Tea Dragon Films is First Adopter in the American Botanical Council's New Adopt-An-Herb Program 2Health News:Tea Dragon Films is First Adopter in the American Botanical Council's New Adopt-An-Herb Program 3Health News:Tea Dragon Films is First Adopter in the American Botanical Council's New Adopt-An-Herb Program 4Health News:A.L.L. Personhood Conference Features Pro-Life New Media Stars 2Health News:MRI Can Spot Presymptomatic MS 2Health News:Top Online Health & Lifestyle Media Brand Inks Major Book Deal 2Health News:Top Online Health & Lifestyle Media Brand Inks Major Book Deal 3Health News:Study first to show that RNA interference can facilitate vaccine development 2Health News:Study first to show that RNA interference can facilitate vaccine development 3Health News:Napo Pharmaceuticals Announces License of Crofelemer to Salix Pharmaceuticals 2Health News:Napo Pharmaceuticals Announces License of Crofelemer to Salix Pharmaceuticals 3Health News:Napo Pharmaceuticals Announces License of Crofelemer to Salix Pharmaceuticals 4Health News:Napo Pharmaceuticals Announces License of Crofelemer to Salix Pharmaceuticals 5
... Plume-inator produces the strongest vacuum ... smoke evacuators. The unit ... hospital grade plug, footswitch, built-in ... purpose swing ring to hold ...
A system for the removal and filtration of laser and surgical smoke....
Stryker Instruments, the leader in surgical helmets, offers its 4th generation of personal protection systems for todays surgical environment the Sterishield T4 System....
... The PS Medical Strata valve is ... the resistance properties of the valve can ... is designed to minimize overdrainage of cerebrospinal ... within a normal physiologic range, regardless of ...
Medicine Products: